The functional interaction between Erα and HIF-1α transduction pathways in breast cancer has been corroborated by evidence showing that HIF-1α may confer resistance to ER antagonists and may be considered as a transcriptional target of Erα [192]. The gene discussed is HIF1A; the disease is breast carcinoma.